Technologies, founded in 1995 in New Orleans, develops
medical diagnostic tests, explores disease mechanisms,
and investigates therapies for autoimmune diseases and
other disorders. In addition, the Company has recently
begun developing anti-viral drugs which are designed to
prevent viral particles from fusing with their target
Many of the Company's products are based on proprietary
technologies it has licensed from Tulane University School
of Medicine. Its products are based on breakthrough research
discoveries, and patents covering most of the products
have been awarded in the U.S. and in other countries.
The Company is developing FF-3, which is an influenza drug with a new method of action, as well as a blood test
to aid in the diagnosis of Lassa fever, a blood test to
aid in the diagnosis of fibromyalgia, a blood test to
aid in the diagnosis of systemic lupus erythematosus,
Sjögren's syndrome, juvenile rheumatoid arthritis and
Grave's disease, and a blood test to detect the presence
of the pro-viral DNA of an inherited retrovirus that appears
to be associated with most cases of breast cancer. Work
on Gulf War Syndrome and other disorders is also under
Autoimmune Technologies is a member of the Viral Hemorraghic Fever Consortium. Information about this exciting group can be found at http://vhfc.org/.
The Company fully supports the Research Investigators' Financial Conflict of Interest ("RIFCOI") regulations, “Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought” (42 CFR Part 50, Subpart F) and “Responsible Prospective Contractors” (45 CFR Part 94), which apply to some of its work. Autoimmune's RIFCOI Policy is available at this link.
The Company's products include the following for: